These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15006108)

  • 1. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial.
    Whynes DK;
    J Med Screen; 2004; 11(1):11-5. PubMed ID: 15006108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.
    Hardcastle JD; Chamberlain JO; Robinson MH; Moss SM; Amar SS; Balfour TW; James PD; Mangham CM
    Lancet; 1996 Nov; 348(9040):1472-7. PubMed ID: 8942775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High participation rates are not necessary for cost-effective colorectal cancer screening.
    Howard K; Salkeld G; Irwig L; Adelstein BA
    J Med Screen; 2005; 12(2):96-102. PubMed ID: 15949121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effective screening strategies for colorectal cancer.
    Whynes DK; Walker AR; Hardcastle JD
    J Public Health Med; 1992 Mar; 14(1):43-9. PubMed ID: 1599742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Planning for a possible national colorectal cancer screening programme.
    Garvican L
    J Med Screen; 1998; 5(4):187-94. PubMed ID: 9934649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of faecal occult blood screening for colorectal cancer: results of the Nottingham trial.
    Whynes DK
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):155-65. PubMed ID: 10612015
    [No Abstract]   [Full Text] [Related]  

  • 10. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia.
    Parekh M; Fendrick AM; Ladabaum U
    Aliment Pharmacol Ther; 2008 Apr; 27(8):697-712. PubMed ID: 18248653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test.
    Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J
    Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia.
    Salkeld G; Young G; Irwig L; Haas M; Glasziou P
    Aust N Z J Public Health; 1996 Apr; 20(2):138-43. PubMed ID: 8799087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal occult blood testing for colorectal cancer: a perspective.
    Barry MJ
    Ann Oncol; 2002 Jan; 13(1):61-4. PubMed ID: 11863113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case-control study to evaluate efficacy of screening for faecal occult blood.
    Lazovich D; Weiss NS; Stevens NG; White E; McKnight B; Wagner EH
    J Med Screen; 1995; 2(2):84-9. PubMed ID: 7497161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of immunochemical tests for colorectal cancer screening.
    Lejeune C; Le Gleut K; Cottet V; Galimard C; Durand G; Dancourt V; Faivre J
    Dig Liver Dis; 2014 Jan; 46(1):76-81. PubMed ID: 24012177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer.
    Robinson MH; Hardcastle JD; Moss SM; Amar SS; Chamberlain JO; Armitage NC; Scholefield JH; Mangham CM
    Gut; 1999 Oct; 45(4):588-92. PubMed ID: 10486370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.